E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe Acute Decompensated Alcoholic Hepatitis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001624 |
E.1.2 | Term | Alcoholic hepatitis |
E.1.2 | System Organ Class | 100000004871 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Efficacy Objective: • To compare the efficacy of orally administered DS102 capsules versus placebo, in the treatment of adult patients with severe acute decompensated Alcoholic Hepatitis (AH). Safety Objective: • To compare the safety of orally administered DS102 capsules versus placebo, in the treatment of adult patients with severe acute decompensated AH. Pharmacokinetic Objective: • To evaluate the pharmacokinetics (PK) of 15(S)-HEPE following orally administered DS102 capsules, in six adult patients with AH in the initial pilot phase of the study, followed by trough level assessment of 15(S)-HEPE in all study participants.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients aged 18 years and older. 2. Total bilirubin of ≥ 5 mg/dl (85μmol/l). 3. Patients with definite or probable AH. 4. MELD ≥18 at baseline visit 5. MDF ≥32 at baseline visit 6. AST >50 U/L 7. Aspartate aminotransferase/alanine aminotransferase (AST:ALT) ratio > 1.5 8. Female patients, or female partners of male patients, of child bearing potential must use highly effective birth control methods or have a sterilised partner for the duration of the study. Highly effective birth control methods are defined as methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include intrauterine device or sexual abstinence. Note: A woman is considered of child bearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Note: Hormonal contraceptives are contraindicated in patients with severe hepatic diseases and are not acceptable as a birth control method in this study. Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. 9. Patient and/or legally authorised representative must provide informed consent. 10. Able to swallow the provided study medication. 11. Not eligible for liver transplant during this hospitalisation. |
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating females. 2. Spontaneous liver function improvement defined by decrease of bilirubin level and MDF of >10% within 5 days of hospital admission. 3. Grade 4 hepatic encephalopathy (West Haven Criteria). 4. Type 1 hepatorenal syndrome (HRS) or a serum creatinine >2 x ULN or the requirement for haemodialysis. 5. History of hypersensitivity to any substance in DS102 capsules or placebo capsules. 6. Alcohol abstinence of >6 weeks prior to screening. 7. Duration of clinically apparent jaundice >3 months prior to baseline. 8. Other causes of liver disease including: a. Evidence of chronic viral hepatitis (Hepatitis B DNA positive or HCV RNA positive). b. Biliary obstruction. c. Hepatocellular carcinoma. d. Wilsons disease. e. Budd Chiari Syndrome. f. Non-alcoholic fatty liver disease. 9. History of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas). 10. Previous entry into the study. 11. AST >400 U/L or ALT >270 U/L. 12. Treatment with any experimental drug within 30 days prior to Day 0 visit (Baseline), or 5 half-lives (whichever is longer). 13. Patients who have used dietary supplements rich in omega-3 oromega-6 fatty acids in the four weeks prior to baseline. 14. Patients dependent on inotropic support (adrenaline or noradrenaline), including Terlipressin. 15. Active variceal hemorrhage on this admission requiring more than 2 units of blood to maintain hemoglobin level within 48 hours 16. Presence of refractory ascites. 17. Untreated or unresolved sepsis. 18. Patients with cerebral hemorrhage, extensive retinal hemorrhage, acute myocardial infarction (within last 6 weeks) or severe cardiac arrhythmias (not including atrial fibrillation). 19. Known infection with HIV at screening. 20. Significant systemic or major illnesses other than liver disease that, in the opinion of the investigator, would preclude or interfere with treatment with DS102 and/or adequate follow up. 21. Previous liver transplantation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Percentage change in MELD score from baseline to Day 28 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Change in total bilirubin from baseline to Day 7, 14, 21 and 28 •Proportion of patients showing a 25% reduction of bilirubin at day 7, 14, 21, and 28. •Change in serum cytokeratin 18-M30/M65 from baseline to Day 7, 14, 21 and 28 •Change in AST levels from Baseline to Day 7, 14, 21 and 28 •Change in AST:ALT ratio from Baseline to Day 7, 14, 21, 28 •Change in MDF score from baseline to Day 7, 14, 21 and 28. •Proportion of patients showing a 25% reduction in MELD score from baseline to Day 7, 14, 21 and 28 •Change in MELD score from baseline to Day 7, 14 and 21 •Change in modified Sequential Organ Failure Assessment (m-SOFA) from baseline to Day 7, 14, 21 and 28 •Proportion of patients with a 2-point worsening of m-SOFA from baseline to Day 7, 14, 21 and 28. •Change in hepatic encephalopathy as assessed by West Haven criteria, from baseline at Day 7, 14, 21 and 28 •Incidence of acute kidney injury over 28 days (defined by requiring medicinal or mechanical support) •Incidence of variceal haemorrhage, ascites or hepatic encephalopathy over 28 days
Exploratory Endpoints •Survival at day 7, 14, 21, 28 and 90 using Kaplan-Meier Plot •Change in Gamma Glutamyl Transferase (GT) from Baseline to Day 7, 14, 21 and 28 •Change in ALT from Baseline to Day 7, 14, 21 and 28. •Change in Child Pugh score from baseline to Day 7, 14, 21 and 28 •Change in APACHE-II score from baseline to Day 7, 14 and 28 •Change in Lille score from baseline to Day 7, 14 and 28
Safety Endpoints •Treatment emergent (S)AE and SUSARs
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 31 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belarus |
Belgium |
France |
Georgia |
Germany |
Latvia |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as ‘last patient last visit (LPLV)’. LPLV is defined as the date the Investigator reviews the last subject’s safety data and determines that no further evaluation is required for the subject to complete the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |